Daily FNArena News - Australia

Further negative news has been forthcoming from ResMed’s SERVE-HF trial which has disappointed brokers.

Weekly update on recommendation, target price, and earnings forecast changes.

Brokers came away from CSR’s investor briefing confident in the outlook for building materials and the company’s position at the forefront of innovation.

FNArena’s weekly update on short positions in the Australian share market.

FNArena provides a weekly update of Australian listed corporate bond issues, current pricing and yield data.

Myer has unveiled its new look. Brokers like the revamped strategy but caution improvements are likely to be slow coming and there are risks.

A summary of the previous session’s corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments.

Law firm Slater & Gordon has improved accounting transparency but the market awaits confirmation from ASIC that there are no further issues.

Woolworths’ FY15 results reveal the extent of the problems the company faces and brokers are mindful the competition will not stand by.

Weekly Update on ASX-listed companies buying in their own stock.